CVS CVS Health

Q1 2025 10-Q

Filed: May 1, 2025Period ending Mar 31, 2025

Consumer Discretionary

Retail-Drug Stores and Proprietary StoresSEC EDGAR

CVS Health (CVS) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Management Discussion & Analysis

• Revenue and profit data not provided in excerpt
• No segment or product line performance details disclosed

+2 more insights

Risk Factors

• No newly added risk factors disclosed this quarter from 10-K
• Most material risk unchanged: reliance on forward-looking statements disclaimers without updates or revisions

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$94.6B

▲ +7.0% YoY

Net Income

$1.8B

▲ +59.8% YoY

Operating Margin

3.6%

▲ +100bp YoY

Net Margin

1.9%

▲ +62bp YoY

EPS (Diluted)

$1.41

▲ +60.2% YoY

Operating Cash Flow

$4.6B

▼ -7.1% YoY

Source: XBRL data from CVS Health Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other CVS Health Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on CVS Health

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.